Dr. Reddy's Laboratories’ arm inks exclusive global license agreement with Olema

10 Jun 2022 Evaluate

Dr. Reddy's Laboratories’ wholly owned subsidiary -- Aurigene Discovery Technologies (Aurigene) and Olema Pharmaceuticals, Inc (Olema) have entered into exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.

Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene program. Aurigene will be eligible for up to $60 million in potential clinical development and regulatory milestones and up to $370 million in potential commercial milestones, as well as royalties ranging from the mid-single digits to the low double digits based on annual net sales. During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts. Olema and Aurigene will jointly direct further preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities. Olema continues to be well capitalized with sufficient cash to fund its planned research and development operations into 2024.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1318.90 12.30 (0.94%)
26-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1784.60
Dr. Reddys Lab 1318.90
Cipla 1357.80
Zydus Lifesciences 938.15
Lupin 2323.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×